drugset
drugset / Trial / NCT07487948

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris

NCT07487948 ↗

Phase 2 Recruiting 30 enrolled Icahn School of Medicine at Mount Sinai LEO Pharma · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).

Timeline

Start
2026-05-19
Primary completion
2027-04-05
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Delgocitinib Small molecule 2 % Topical

Indications

central centrifugal cicatricial alopecia lichen planopilaris